Want to see MDXH full AI Analyst Report?
MDXH Stock Chart & Stats
$0.79
-$0.01(-2.91%)
At close: 4:00 PM EDT
$0.79
-$0.01(-2.91%)
Day’s Range― - ―
52-Week Range$0.40 - $5.33
Previous CloseN/A
Volume391.95K
Average Volume (3M)690.00K
Market Cap
$53.93M
Enterprise Value$107.73
Total Cash (Recent Filing)$19.21M
Total Debt (Recent Filing)$105.85M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Nov 12, 2026EPS Estimate
-0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding95,417,380
10 Day Avg. Volume211,779
30 Day Avg. Volume689,996
Financial Highlights & Ratios
PEG Ratio0.38
Price to Book (P/B)-14.77
Price to Sales (P/S)1.66
P/FCF Ratio-15.43
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside89.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.51
Revenue Forecast (FY)$111.18M
Bulls Say, Bears Say
Bulls Say
Revenue GrowthMDxHealth has achieved substantial multi-year revenue scaling, demonstrating growing adoption of its molecular diagnostic portfolio. Continued year-over-year growth and management’s reiterated 2026 guidance indicate that demand expansion may remain a meaningful support for the business over the next several quarters.
Healthy Gross MarginsGross margins above 60% show that the company’s testing model generates meaningful profit per test before operating expenses. This provides operating leverage if volume continues to grow, while the higher Q2 gross profit indicates that expanding revenue can support future progress toward profitability.
Clinical And Product DevelopmentPeer-reviewed clinical evidence can strengthen physician confidence and support the role of MDxHealth tests in clinical decisions. Ongoing AI initiatives and visibility into additional study data also provide avenues to expand product value and reinforce the company’s position in urologic diagnostics.
Bears Say
Persistent Operating LossesThe company’s revenue growth has not yet translated into sustainable profitability. Rising operating expenses, particularly those tied to ExoDx integration, are causing losses to widen and may delay the benefits of scale, limiting internal funding capacity until cost discipline and acquisition synergies improve.
Balance Sheet And Funding StrainHigher debt, negative shareholders’ equity, and continued cash burn materially reduce financial flexibility. The company remains dependent on operating improvement or additional external capital to meet obligations, increasing financing and dilution risk and leaving less capacity to absorb execution setbacks.
Resolve Business DiscontinuationThe reimbursement-driven exit from Resolve UTI testing removes a revenue activity and demonstrates the business’s exposure to payer decisions. Customer transitions and the associated wind-down also consume management attention, while the loss of the operation narrows portfolio breadth during a period of integration and recovery.
MDxHealth News
MDXH FAQ
What was MDxHealth’s price range in the past 12 months?
MDxHealth lowest stock price was $0.40 and its highest was $5.33 in the past 12 months.
What is MDxHealth’s market cap?
MDxHealth’s market cap is $53.93M.
When is MDxHealth’s upcoming earnings report date?
MDxHealth’s upcoming earnings report date is Nov 12, 2026 which is in 43 days.
How were MDxHealth’s earnings last quarter?
MDxHealth released its earnings results on Aug 13, 2026. The company reported -$0.18 earnings per share for the quarter, beating the consensus estimate of -$0.193 by $0.013.
Is MDxHealth overvalued?
According to Wall Street analysts MDxHealth’s price is currently Undervalued.
Does MDxHealth pay dividends?
MDxHealth does not currently pay dividends.
What is MDxHealth’s EPS estimate?
MDxHealth’s EPS estimate is -0.09.
How many shares outstanding does MDxHealth have?
MDxHealth has 95,417,380 shares outstanding.
What happened to MDxHealth’s price movement after its last earnings report?
MDxHealth reported an EPS of -$0.18 in its last earnings report, beating expectations of -$0.193. Following the earnings report the stock price went up 74.892%.
Which hedge fund is a major shareholder of MDxHealth?
Currently, no hedge funds are holding shares in MDXH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MDxHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (89.87% Upside)
$1.50 (89.87% Upside)
Blogger Sentiment
Neutral
MDXH Sentiment 50%
Sector Average 64%
Sector Average 64%
Insider Transactions
Bought Shares
Worth $991.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.81%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MDxHealth
MDxHealth SA is a commercial-stage precision diagnostics firm delivering specialized urologic solutions across the globe. Its international footprint includes the United States, various European nations such as the Netherlands, Belgium, Spain, Poland, Italy, and the wider European Union. The company's innovative genomic testing portfolio for prostate cancer comprises SelectMDx, a non-invasive urine test, and ConfirmMDx, an epigenetic diagnostic tool. These advanced offerings enable medical professionals to precisely identify clinically significant prostate cancer, thereby minimizing reliance on invasive procedures and their associated risks. Established in 2003, with its headquarters in Herstal, Belgium, the entity was formerly known as OncoMethylome Sciences SA until its renaming to MDxHealth SA in October 2010.
MDXH Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong operational and strategic progress — significant sequential revenue acceleration, a successful customer transition, removal of a $10.4M contingent liability, clinical data momentum, and a $20M capital raise — alongside meaningful near-term financial challenges including wider operating and net losses, negative adjusted EBITDA, gross margin compression, and tissue volumes still down year-over-year. Management reiterated full-year revenue guidance ($110M–$115M) and a path to adjusted EBITDA positivity by year-end, striking an overall tone of cautious optimism while acknowledging current profitability headwinds.View all MDXH earnings summariesMDXH Stock 12 Month Forecast
Average Price Target
$1.50
▲(89.87% Upside)
Technical Analysis
Ownership Overview
7.23% Insiders
0.10% Mutual Funds
14.27% Other Institutional Investors
78.26% Public Companies and
Individual Investors